Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.98 -1.0%	$3.25	$2.07 ▼ $4.20	$95.99M	0.43	107,546 shs	165,214 shs
BDRX Biodexa Pharmaceuticals	$7.13 +4.9%	$9.14	$5.85 ▼ $163.10	$26.06M	0.98	148,135 shs	23,694 shs
ONCY Oncolytics Biotech	$0.86 -6.2%	$0.86	$0.33 ▼ $1.53	$83.62M	1.09	960,919 shs	987,393 shs
PLRX Pliant Therapeutics	$1.66 -1.2%	$1.44	$1.10 ▼ $16.10	$101.90M	1.42	1.04 million shs	813,189 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	0.00%	-1.00%	-5.10%	+14.18%	-1.32%
BDRX Biodexa Pharmaceuticals	0.00%	+6.42%	-19.84%	-49.43%	+712,999,900.00%
ONCY Oncolytics Biotech	0.00%	-13.29%	-23.01%	+65.33%	-13.75%
PLRX Pliant Therapeutics	0.00%	+5.06%	+18.57%	+17.73%	-86.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	3.4625 of 5 stars	3.5	5.0	0.0	3.1	3.3	0.0
BDRX Biodexa Pharmaceuticals	0.152 of 5 stars	0.0	2.0	0.0	2.4	0.0	0.0
ONCY Oncolytics Biotech	2.2802 of 5 stars	3.4	5.0	0.0	2.4	0.0	0.0
PLRX Pliant Therapeutics	3.7588 of 5 stars	3.0	3.0	4.7	1.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.00	Buy	$9.00	202.01% Upside
BDRX Biodexa Pharmaceuticals	0.00	N/A	N/A	N/A
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	404.82% Upside
PLRX Pliant Therapeutics	2.08	Hold	$8.19	393.22% Upside

Current Analyst Ratings Breakdown

Latest BDRX, PLRX, ANIX, and ONCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	PLRX Pliant Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$17.00 ➝ $4.00
8/5/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	457.08	N/A	N/A	$0.59 per share	5.05
BDRX Biodexa Pharmaceuticals	$470K	55.37	N/A	N/A	$2.91 per share	2.45
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.05 per share	N/A
PLRX Pliant Therapeutics	$1.58M	64.50	N/A	N/A	$5.00 per share	0.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.38	N/A	∞	N/A	N/A	-68.17%	-60.38%	9/5/2025 (Estimated)
BDRX Biodexa Pharmaceuticals	-$7.32M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	-$23.14M	-$0.29	N/A	N/A	N/A	N/A	-313.77%	-130.19%	N/A
PLRX Pliant Therapeutics	-$210.30M	-$3.61	N/A	N/A	N/A	N/A	-68.45%	-52.29%	N/A

Latest BDRX, PLRX, ANIX, and ONCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/5/2025	Q3 2025	ANIX Anixa Biosciences	-$0.10	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	ONCY Oncolytics Biotech	-$0.11	-$0.05	+$0.06	-$0.05	N/A	N/A
8/7/2025	Q2 2025	PLRX Pliant Therapeutics	-$0.62	-$0.71	-$0.09	-$0.71	N/A	N/A
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.89	8.89
BDRX Biodexa Pharmaceuticals	0.01	1.75	1.75
ONCY Oncolytics Biotech	N/A	3.20	3.20
PLRX Pliant Therapeutics	N/A	11.03	11.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
BDRX Biodexa Pharmaceuticals	17.51%
ONCY Oncolytics Biotech	6.82%
PLRX Pliant Therapeutics	97.30%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
BDRX Biodexa Pharmaceuticals	0.34%
ONCY Oncolytics Biotech	0.10%
PLRX Pliant Therapeutics	8.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.21 million	24.06 million	Optionable
BDRX Biodexa Pharmaceuticals	20	3.65 million	3.64 million	Not Optionable
ONCY Oncolytics Biotech	30	97.41 million	97.31 million	Not Optionable
PLRX Pliant Therapeutics	90	61.39 million	56.48 million	Optionable

BDRX, PLRX, ANIX, and ONCY Headlines

Recent News About These Companies

Piper Sandler Issues Pessimistic Forecast for Pliant Therapeutics (NASDAQ:PLRX) Stock Price

2 hours ago | americanbankingnews.com

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Hold" from Brokerages

August 9 at 9:31 AM | marketbeat.com

Pliant Therapeutics (NASDAQ:PLRX) Price Target Lowered to $4.00 at Piper Sandler

August 9 at 8:56 AM | marketbeat.com

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 7 at 4:18 PM | globenewswire.com

XTX Topco Ltd Makes New $630,000 Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

August 6, 2025 | marketbeat.com

Pliant Therapeutics (PLRX) to Release Earnings on Wednesday

August 5, 2025 | americanbankingnews.com

Pliant Therapeutics (PLRX) Expected to Announce Earnings on Wednesday

July 30, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN)

July 24, 2025 | theglobeandmail.com

Peapod Lane Capital LLC Acquires New Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

July 10, 2025 | marketbeat.com

Pliant Therapeutics Provides Update on BEACON-IPF

June 27, 2025 | globenewswire.com

Alnylam, Pliant among stocks yet to face Q2 catalysts: Wells Fargo

June 7, 2025 | msn.com

Pliant Therapeutics presents new fibrosis treatment data

May 23, 2025 | investing.com

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025 | finance.yahoo.com

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025 | globenewswire.com

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Pliant Therapeutics announces workforce reduction

May 3, 2025 | uk.investing.com

Pliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical Trials

May 3, 2025 | nasdaq.com

Bay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in value

May 2, 2025 | msn.com

Pliant Axes 45% of Workforce To Save Cash, Support Late-Stage Clinical Trials

May 2, 2025 | biospace.comB

Pliant Therapeutics cuts workforce by 45% after bexotegrast trial safety woes

May 2, 2025 | fiercebiotech.comF

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

May 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
This Drone Stock Is on Sale Despite Big Army Contract
By Jeffrey Neal Johnson | July 31, 2025
View This Drone Stock Is on Sale Despite Big Army Contract
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX
By Leo Miller | August 6, 2025
View Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX

BDRX, PLRX, ANIX, and ONCY Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$2.98 -0.03 (-1.00%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$3.03 +0.05 (+1.68%)

As of 08/8/2025 06:42 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Biodexa Pharmaceuticals NASDAQ:BDRX

$7.13 +0.33 (+4.85%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$7.10 -0.03 (-0.42%)

As of 08/8/2025 07:53 PM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Oncolytics Biotech NASDAQ:ONCY

$0.86 -0.06 (-6.20%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.84 -0.02 (-2.14%)

As of 08/8/2025 07:38 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Pliant Therapeutics NASDAQ:PLRX

$1.66 -0.02 (-1.19%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.62 -0.04 (-2.65%)

As of 08/8/2025 07:18 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time